Cargando…
Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone
INTRODUCTION: Twenty-five percent of stage II colon cancer (CC) patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery. We hypothesise that subtypes of MRD, defined by circulating tumour cells (CTCs) and bone marrow micrometastasis (mM), have different types...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652547/ https://www.ncbi.nlm.nih.gov/pubmed/33209110 http://dx.doi.org/10.3332/ecancer.2020.1119 |
_version_ | 1783607711292719104 |
---|---|
author | Murray, Nigel P Aedo, Socrates Villalon, Ricardo Albarran, Vidal Orrego, Shenda Guzman, Eghon |
author_facet | Murray, Nigel P Aedo, Socrates Villalon, Ricardo Albarran, Vidal Orrego, Shenda Guzman, Eghon |
author_sort | Murray, Nigel P |
collection | PubMed |
description | INTRODUCTION: Twenty-five percent of stage II colon cancer (CC) patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery. We hypothesise that subtypes of MRD, defined by circulating tumour cells (CTCs) and bone marrow micrometastasis (mM), have different types and kinetics of relapse. METHODS AND PATIENTS: One month after surgery, blood and bone marrow samples were taken to detect CTCs and mM using immunocytochemistry with anti-carcinoembryonic antigen (CEA). Follow-up was for up to 5 years or relapse. Disease-free survival curves using Kaplan–Meier (DFS) and restricted mean disease-free survival times (RMST) were calculated for three prognostic groups: A: MRD (−), B: mM (+) CTC (−) MRD and C: CTC (+) MRD. RESULTS: One hundred and eighty-one patients (82 men) have participated, mean age was 68 years and median follow-up was 4.04 years (A (N = 105), B (N = 36) and C (N = 40)). For the whole cohort of 5 years, DFS was 70%, median DFS has not reached (Groups A: 98%, B: 63% and C: 7%) and median DFS for Groups A and B have not reached. RMST for the whole cohort of 4.1 years, Group A was 4.9 years, B was 4.1 years and C was 1.7 years. Serum CEA was significantly higher in Group C. No significant differences for sex, age or high-risk adverse prognostic factors between groups were detected. CONCLUSIONS: MRD subtypes define relapse patterns and may be useful to define the risk of relapse in stage II CC patients, in which patients may benefit or not from additional therapy and warrants further studies with a larger number of patients. |
format | Online Article Text |
id | pubmed-7652547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-76525472020-11-17 Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone Murray, Nigel P Aedo, Socrates Villalon, Ricardo Albarran, Vidal Orrego, Shenda Guzman, Eghon Ecancermedicalscience Research INTRODUCTION: Twenty-five percent of stage II colon cancer (CC) patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery. We hypothesise that subtypes of MRD, defined by circulating tumour cells (CTCs) and bone marrow micrometastasis (mM), have different types and kinetics of relapse. METHODS AND PATIENTS: One month after surgery, blood and bone marrow samples were taken to detect CTCs and mM using immunocytochemistry with anti-carcinoembryonic antigen (CEA). Follow-up was for up to 5 years or relapse. Disease-free survival curves using Kaplan–Meier (DFS) and restricted mean disease-free survival times (RMST) were calculated for three prognostic groups: A: MRD (−), B: mM (+) CTC (−) MRD and C: CTC (+) MRD. RESULTS: One hundred and eighty-one patients (82 men) have participated, mean age was 68 years and median follow-up was 4.04 years (A (N = 105), B (N = 36) and C (N = 40)). For the whole cohort of 5 years, DFS was 70%, median DFS has not reached (Groups A: 98%, B: 63% and C: 7%) and median DFS for Groups A and B have not reached. RMST for the whole cohort of 4.1 years, Group A was 4.9 years, B was 4.1 years and C was 1.7 years. Serum CEA was significantly higher in Group C. No significant differences for sex, age or high-risk adverse prognostic factors between groups were detected. CONCLUSIONS: MRD subtypes define relapse patterns and may be useful to define the risk of relapse in stage II CC patients, in which patients may benefit or not from additional therapy and warrants further studies with a larger number of patients. Cancer Intelligence 2020-10-08 /pmc/articles/PMC7652547/ /pubmed/33209110 http://dx.doi.org/10.3332/ecancer.2020.1119 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Murray, Nigel P Aedo, Socrates Villalon, Ricardo Albarran, Vidal Orrego, Shenda Guzman, Eghon Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone |
title | Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone |
title_full | Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone |
title_fullStr | Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone |
title_full_unstemmed | Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone |
title_short | Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone |
title_sort | subtypes of minimal residual disease and outcome for stage ii colon cancer treated by surgery alone |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652547/ https://www.ncbi.nlm.nih.gov/pubmed/33209110 http://dx.doi.org/10.3332/ecancer.2020.1119 |
work_keys_str_mv | AT murraynigelp subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone AT aedosocrates subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone AT villalonricardo subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone AT albarranvidal subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone AT orregoshenda subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone AT guzmaneghon subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone |